title: Oral administration in combination with zinc enhances beta-cryptoxanthin-induced anabolic effects on bone components in the femoral tissues of rats in vivo.
abstract: The effects of combined beta-cryptoxanthin and zinc on bone components in the femoral-diaphyseal (cortical bone) and -metaphyseal (trabecular bone) tissues of rats in vivo were investigated. Rats were orally administered either vehicle, beta-cryptoxanthin (5 or 10 microg/100 g body weight), zinc sulfate (0.1 or 0.5 mg Zn/100 g), or their combination once a day for 7 d. Calcium content, alkaline phosphatase activity, and DNA content in the femoral-diaphyseal tissues was not significantly altered by the administration of beta-cryptoxanthin (5 microg/100 g) or zinc (0.1 or 0.5 mg/100 g). Combined administration of beta-cryptoxanthin (5 microg/100 g) and zinc (0.1 or 0.5 mg/100 g) caused a synergistic increase in calcium content, alkaline phosphatase activity, and DNA content in the diaphyseal tissues. The effect of beta-cryptoxanthin (5 or 10 microg/100 g) in increasing calcium and DNA contents in the metaphyseal tissues was significantly enhanced by the combined administration of zinc (0.1 or 0.5 mg/100 g), but did not have a significant effect on the metaphyseal components. The metaphyseal alkaline phosphatase activity was markedly increased by the combination of beta-cryptoxanthin (5 microg/100 g) and zinc (0.1 or 0.5 mg/100 g). This study demonstrates that the oral administration of the combination of zinc at lower doses synergistically enhances beta-cryptoxanthin-induced anabolic effects on bone components in the femoral tissues of rats in vivo.
authors.affiliation: Laboratory of Endocrinology and Molecular Metabolism, Graduate School of Nutritional Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan. yamaguch@u-shizuoka-ken.ac.jp
authors.forename: Masayoshi
authors.initials: M
authors.lastname: Yamaguchi
authors.forename: Satoshi
authors.initials: S
authors.lastname: Uchiyama
authors.forename: Kaori
authors.initials: K
authors.lastname: Ishiyama
authors.forename: Ken
authors.initials: K
authors.lastname: Hashimoto
mesh_terms: D000284:Administration, Oral; D000469:Alkaline Phosphatase / Q000378:metabolism; D045930:Anabolic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D002118:Calcium / Q000097:blood; D065366:Cryptoxanthins; D004357:Drug Synergism; D005269:Femur / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism; D008297:Male; D017553:Phosphorus Compounds / Q000097:blood; D051381:Rats; D017208:Rats, Wistar; D024341:Xanthophylls; D015032:Zinc / Q000097:blood; D019287:Zinc Sulfate / Q000008:administration & dosage / Q000494:pharmacology*; D019207:beta Carotene / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: D045930:Anabolic Agents; D065366:Cryptoxanthins; D017553:Phosphorus Compounds; D024341:Xanthophylls; D019207:beta Carotene; D019287:Zinc Sulfate; D000469:Alkaline Phosphatase; D015032:Zinc; D002118:Calcium